Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 19, Art. 81 (pp. 1143-1154)    |    2018       

»

Neurotic disturbances and testosterone production in young healthy male

Stepanenko I.A., Salukhov V.V., Kitsyshin V.P., Izilyaeva E.A., Novikov I.I., Shalnev M.P., Surzhikov P.V., Meshkova M.E., Sukhina I.A., Makhova E.A., Yusupov V.V., Zelenina N.V., Kravchenko Y.V., Serova Y.S., Levich S.N.

S.M. Kirov Military Medical Academy, Saint Petersburg, Russia

Brief summary

A decrease in testosterone levels in men can occur because of both pathological and functional changes in the body. Functional hypogonadism may accompany a variety of chronic conditions, but also be the result of physical or psychological stress. The literature suggests in favor of both the existing and the missing relationship between testosterone levels and neurotic disorders. Surveyed 88 healthy males aged 18-20 years. The analysis of the obtained data did not reveal a statistically significant relationship between the level of total testosterone and the data of psychological examination for neurotic disorders. Thus, the relationship between the level of testosterone and the severity of neurotic syndromes in young healthy males has not been confirmed.


Key words

testosterone, neurotic disorders, depression, functional hypogonadism.

Reference list

1. Walters, K.A. Evidence from animal models on the pathogenesis of PCOS / K.A. Walters, M.J. Bertoldo, D.J. Handelsman // Best Pract. Res. Clin. Endocrinol. Metab. - 2018. - Vol. 32, N 3. - P. 271-281.


2. Endocrine and metabolic evaluation of classic Klinefelter syndrome and high-grade aneuploidies of sexual chromosomes with male phenotype: are they different clinical conditions? / M. Spaziani [et al.] // Eur. J. Endocrinol. - 2018. - Vol. 178, N 4. - P. 343-352.


3. Delayed puberty versus hypogonadism: a challenge for the pediatrician / M. Bozzola [et al.] // Ann. Pediatr. Endocrinol. Metab. - 2018. - Vol. 23, N 2. - P. 57-61.


4. Pediatric anosmia: A case series / L.J. Hauser [et al.] // Int. J. Pediatr. Otorhinolaryngol. - 2018. - Vol. 110. - P. 135-139.


5. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging / S.M. Harman [et al.] // J. Clin. Endocrinol. Metab. - 2001. - Vol. 86, N 2. - P. 724-731.


6. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men / J.E. Morley [et al.] // Metabolism. - 1997. - Vol. 46, N 4. - P. 410-413.


7. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study / A. Aversa [et al.] // J. Sex. Med. - 2010. - Vol. 7, N 10. - P. 3495-3503.


8. Han, T.S. What is the optimal therapy for young males with hypogonadotropic hypogonadism? / T.S. Han, P.M.G. Bouloux // Clin. Endocrinol. (Oxf.). - 2010. - Vol. 72, N 6. - P. 731-737.


9. Kalyani, R.R. Male hypogonadism in systemic disease / R.R. Kalyani, S. Gavini, A.S. Dobs // Endocrinol. Metab. Clin. North Am. - 2007. - Vol. 36, N 2. - P. 333-348.


10. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies / J.S. Brand [i dr.] // PloS One. - 2014. - T. 9, ? 7. - S. e100409.


11. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study / A. Tajar [i dr.] // J. Clin. Endocrinol. Metab. - 2010. - T. 95, ? 4. - S. 1810-1818.


12. Natural history, risk factors and clinical features of primary hypogonadism in ageing men: Longitudinal Data from the European Male Ageing Study / T. Ahern [et al.] // Clin. Endocrinol. (Oxf.). - 2016. - Vol. 85, N 6. - P. 891-901.


13. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes / C. Wang [et al.] // Diabetes Care. - 2011. - Vol. 34, N 7. - P. 1669-1675.


14. Reversal of Idiopathic Hypogonadotropic Hypogonadism / T. Raivio [et al.] // N. Engl. J. Med. - 2007. - Vol. 357, N 9. - P. 863-873.


15. Reversal and relapse of hypogonadotropic hypogonadism: resilience and fragility of the reproductive neuroendocrine system / V.F. Sidhoum [et al.] // J. Clin. Endocrinol. Metab. - 2014. - Vol. 99, N 3. - P. 861-870.


16. Reversal of idiopathic hypogonadotropic hypogonadism: a cohort study in Chinese patients / J.-F. Mao [et al.] // Asian J. Androl. - 2015. - Vol. 17, N 3. - P. 497-502.


17. Increased incidence of diagnosed depressive illness in hypogonadal older men / M.M. Shores [et al.] // Arch. Gen. Psychiatry. - 2004. - Vol. 61, N 2. - P. 162-167.


18. Testosterone and depression: systematic review and meta-analysis / F.A. Zarrouf [et al.] // J. Psychiatr. Pract. - 2009. - Vol. 15, N 4. - P. 289-305.


19. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer / C.J. DiBlasio [et al.] // Can. J. Urol. - 2008. - Vol. 15, N 5. - P. 4249-4256; discussion 4256.


20. Rabkin, J.G. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms / J.G. Rabkin, G.J. Wagner, R. Rabkin // Arch. Gen. Psychiatry. - 2000. - Vol. 57, N 2. - P. 141-147; discussion 155-156.


21. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study / C. Wang [i dr.] // J. Clin. Endocrinol. Metab. - 1996. - T. 81, ? 10. - S. 3578-3583.


22. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial / H.G. Pope [et al.] // Am. J. Psychiatry. - 2003. - Vol. 160, N 1. - P. 105-111.


23. Testosterone supplementation for depressed men: current research and suggested treatment guidelines / G. Kanayama [et al.] // Exp. Clin. Psychopharmacol. - 2007. - Vol. 15, N 6. - P. 529-538.


24. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial / S.N. Seidman [et al.] // J. Clin. Psychiatry. - 2001. - Vol. 62, N 6. - P. 406-412.


25. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss / A.M. Kenny [et al.] // J. Gerontol. A. Biol. Sci. Med. Sci. - 2004. - Vol. 59, N 1. - P. 75-78.


26. Surampudi, P.N. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy / P.N. Surampudi, C. Wang, R. Swerdloff // Int. J. Endocrinol. - 2012. - Vol. 2012. - P. 625434.


27. Submitting to defeat: social anxiety, dominance threat, and decrements in testosterone / J.K. Maner [et al.] // Psychol. Sci. - 2008. - Vol. 19, N 8. - P. 764-768.


28. Salivary testosterone: associations with depression, anxiety disorders, and antidepressant use in a large cohort study / E.J. Giltay [et al.] // J. Psychosom. Res. - 2012. - Vol. 72, N 3. - P. 205-213.


29. Barrett-Connor, E. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study / E. Barrett-Connor, D.G. Von Mühlen, D. Kritz-Silverstein // J. Clin. Endocrinol. Metab. - 1999. - Vol. 84, N 2. - P. 573-577.


30. Associations between sex steroid hormone levels and depressive symptoms in elderly men and women: results from the Health ABC study / L.F.J. Morsink [et al.] // Psychoneuroendocrinology. - 2007. - Vol. 32, N 8-10. - P. 874-883.